Neurodoron® for Stress Impairments: A Prospective, Multicenter Non-Interventional Trial

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Mar 7

PMID 35251205

Authors

Juliane Hellhammer

Katja Schmidt

Cristina Semaca

Rebecca Hufnagel

Affiliations

Soon will be listed here.

Abstract

Introduction: Stress is associated with a multitude of physical and psychological health impairments. To tackle these health disorders, over-the-counter (OTC) products like Neurodoron® are popular since they are considered safe and tolerable. Experience reports and first studies indicate that Neurodoron® is efficient in the treatment of stress-associated health symptoms. To confirm this, a non-interventional study (NIS) with pharmacies was conducted.

Methods: The NIS was planned to enroll female and male patients who suffered from nervous exhaustion with symptoms caused by acute and/or chronic stress. The main outcome measures were characteristic stress symptoms, stress burden, and perceived stress. Further outcome measures included perceived efficacy and tolerability of the product as assessed by the patients and collection of adverse drug reactions (ADRs). A study duration of about 21 days with a recommended daily dose of 3-4 tablets was set.

Results: 279 patients were enrolled at 74 German pharmacies. The analyzed set (AS) included 272 patients (mean age 44.8 ± 14.4 years, 73.9% female). 175 patients of the AS completed the NIS. During the study, all stress symptoms declined significantly (total score 18.1 vs. 12.1 (of max. 39 points), < 0.0001). Furthermore, a reduction of stress burden (relative difference in stress burden, VAS = -29.1%, < 0.0001) was observed. For most patients, perceived stress was reduced at the study end (PSQ total score decreased in 70.9% of the patients). 75.9% of the study population rated the product efficacy as "good" or "very good" and 96.6% rated its tolerability as "good" or "very good." One uncritical ADR was reported. . This study adds information on the beneficial effects of Neurodoron® in self-medication. The results from this NIS showed a marked reduction in stress burden and perceived stress, along with an excellent safety profile of the medicinal product (MP) Neurodoron®. Further trials are required to confirm these results.

References

Andlin-Sobocki P, Jonsson B, Wittchen H, Olesen J . Cost of disorders of the brain in Europe. Eur J Neurol. 2005; 12 Suppl 1:1-27. DOI: 10.1111/j.1468-1331.2005.01202.x. View

Anglemyer A, Horvath H, Bero L . Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; (4):MR000034. PMC: 8191367. DOI: 10.1002/14651858.MR000034.pub2. View

Taylor-Piliae R, Morrison H, Hsu C, Whitman S, Grandner M . The Feasibility of Tai Chi Exercise as a Beneficial Mind-Body Intervention in a Group of Community-Dwelling Stroke Survivors with Symptoms of Depression. Evid Based Complement Alternat Med. 2021; 2021:8600443. PMC: 8577891. DOI: 10.1155/2021/8600443. View

Fischer T, Reuter M, Riedl R . The Digital Stressors Scale: Development and Validation of a New Survey Instrument to Measure Digital Stress Perceptions in the Workplace Context. Front Psychol. 2021; 12:607598. PMC: 7994533. DOI: 10.3389/fpsyg.2021.607598. View

Hamre H, Glockmann A, Heckenbach K, Matthes H . Use and Safety of Anthroposophic Medicinal Products: An Analysis of 44,662 Patients from the EvaMed Pharmacovigilance Network. Drugs Real World Outcomes. 2017; 4(4):199-213. PMC: 5684047. DOI: 10.1007/s40801-017-0118-5. View

McEwen B . Neurobiological and Systemic Effects of Chronic Stress. Chronic Stress (Thousand Oaks). 2017; 1. PMC: 5573220. DOI: 10.1177/2470547017692328. View

Busch M, Maske U, Ryl L, Schlack R, Hapke U . [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56(5-6):733-9. DOI: 10.1007/s00103-013-1688-3. View

Dantzer R . Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol Rev. 2018; 98(1):477-504. PMC: 5866360. DOI: 10.1152/physrev.00039.2016. View

EISENBERG D, Davis R, Ettner S, Appel S, Wilkey S, Van Rompay M . Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998; 280(18):1569-75. DOI: 10.1001/jama.280.18.1569. View

10.

Afrasiabian F, Mirabzadeh Ardakani M, Rahmani K, Azadi N, Alemohammad Z, Bidaki R . Aloysia citriodora Palau (lemon verbena) for insomnia patients: A randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Phytother Res. 2018; 33(2):350-359. DOI: 10.1002/ptr.6228. View

11.

Mason J . A review of psychoendocrine research on the sympathetic-adrenal medullary system. Psychosom Med. 1968; 30(5):Suppl:631-53. DOI: 10.1097/00006842-196809000-00022. View

12.

Stub T, Kristoffersen A, Overvag G, Jong M, Musial F, Liu J . Adverse effects in homeopathy. A systematic review and meta-analysis of observational studies. Explore (NY). 2020; 18(1):114-128. DOI: 10.1016/j.explore.2020.11.008. View

13.

The Lancet Global Health . Mental health matters. Lancet Glob Health. 2020; 8(11):e1352. PMC: 7561290. DOI: 10.1016/S2214-109X(20)30432-0. View

14.

Wagner P, Jester D, Leclair B, TAYLOR A, Woodward L, Lambert J . Taking the edge off: why patients choose St. John's Wort. J Fam Pract. 1999; 48(8):615-9. View

15.

Nakao M . Work-related stress and psychosomatic medicine. Biopsychosoc Med. 2010; 4(1):4. PMC: 2882896. DOI: 10.1186/1751-0759-4-4. View

16.

Ghadimi M, Foroughi F, Hashemipour S, Nooshabadi M, Ahmadi M, Ahadi Nezhad B . Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes. Phytother Res. 2020; 35(2):1023-1032. DOI: 10.1002/ptr.6867. View

17.

Russell A, Tasker J, Lucion A, Fiedler J, Munhoz C, Wu T . Factors promoting vulnerability to dysregulated stress reactivity and stress-related disease. J Neuroendocrinol. 2018; 30(10):e12641. PMC: 6181794. DOI: 10.1111/jne.12641. View

18.

Mishra D, Vora J . Non interventional drug studies in oncology: Why we need them?. Perspect Clin Res. 2011; 1(4):128-33. PMC: 3043359. DOI: 10.4103/2229-3485.71770. View

19.

Cohen S, Janicki-Deverts D, Miller G . Psychological stress and disease. JAMA. 2007; 298(14):1685-7. DOI: 10.1001/jama.298.14.1685. View

20.

Slavich G, Irwin M . From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014; 140(3):774-815. PMC: 4006295. DOI: 10.1037/a0035302. View